Gain Therapeutics’ (GANX) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report published on Friday morning,Benzinga reports. Chardan Capital currently has a $6.00 price objective on the stock.

Several other equities research analysts have also commented on GANX. Scotiabank assumed coverage on Gain Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price objective for the company. Roth Mkm reiterated a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a research report on Tuesday, December 24th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, March 17th. Finally, Roth Capital raised shares of Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Stock Performance

Shares of GANX stock opened at $1.89 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $4.04. The firm has a market capitalization of $50.13 million, a price-to-earnings ratio of -1.72 and a beta of 0.14. The business has a fifty day moving average of $2.22 and a 200 day moving average of $2.07.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. As a group, research analysts expect that Gain Therapeutics will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its holdings in Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock worth $212,000 after buying an additional 44,750 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after acquiring an additional 88,236 shares during the period. Benedict Financial Advisors Inc. purchased a new stake in shares of Gain Therapeutics during the 4th quarter worth approximately $35,000. Sprott Inc. acquired a new stake in shares of Gain Therapeutics in the 4th quarter worth approximately $30,000. Finally, Northern Trust Corp increased its stake in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares in the last quarter. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.